Company: WHWK
Filing Date: 2025-03-26
Form Type: 8-K
Source: 0001193125-25-063253
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-26
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item 2.01.      Completion of Acquisition or Disposition of Assets.  

On March 25, 2025, Whitehawk Therapeutics, Inc. (the “ Company”) completed its previously announced sale of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (the “ Divestiture”) pursuant to the Stock Purchase Agreement (the “ Purchase Agreement”) entered into with KAKEN INVESTMENTS INC., a Delaware corporation (“ Purchaser”), KAKEN PHARMACEUTICAL CO., LTD, and Aadi Subsidiary, Inc. on December 19, 2024. In accordance with the Purchase Agreement, upon the closing of the Divestiture, Purchaser paid to the Company a cash payment of $102.4 million (following applicable purchase price adjustments under the Purchase Agreement).

The foregoing description of the Divestiture and the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filedwith the Securities and Exchange Commission on December 20, 2024 and is incorporated herein by reference.